{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-026995","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2023-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.000942+00:00","generated_at":"2026-06-18T18:07:19.387952+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rhythm Pharma Q4 2022 product revenue $8.8M, net loss $42.5M; BBS launch >200 scripts","bullets":["Product revenue $8.8M Q4 2022, $16.9M FY; net loss $42.5M ($0.75/sh) Q4, $181.1M ($3.47/sh) FY.","IMCIVREE for BBS: >200 new scripts from >125 physicians, >100 reimbursement approvals since FDA approval June 2022.","Acquired Xinvento B.V. for congenital hyperinsulinism; founder Claudine van der Sande joins as VP, Head of CHI Program.","Initiated pivotal Phase 3 trial for setmelanotide in acquired hypothalamic obesity; patient screening underway.","FY 2023 non-GAAP operating expense guidance $200M-$220M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-026995","json":"https://secwatch.observer/filing/0001104659-23-026995.json","markdown":"https://secwatch.observer/filing/0001104659-23-026995.md","text":"https://secwatch.observer/filing/0001104659-23-026995.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923026995/0001104659-23-026995-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923026995/tm237866d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T18:07:19.387952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a855c90dcf9e690c1e073a2a11acd7fe5ea68e2b","claim":"RHYTHM PHARMACEUTICALS, INC. reported the fourth quarter ended December 31, 2022 results: revenue $8.8 million.","evidence_excerpt":"• Revenue: Product revenue, net relating to global sales of IMCIVREE was $8.8 million for the fourth quarter of 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923026995/0001104659-23-026995-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$8.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ac4009d13be642e35384717ba890e074bf526dd3","claim":"RHYTHM PHARMACEUTICALS, INC. reported the year ended December 31, 2022 results: revenue $16.9 million.","evidence_excerpt":"as $8.8 million for the fourth quarter of 2022 and $16.9 million for the year ended Decem","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923026995/0001104659-23-026995-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$16.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}